Alexandre Harari

Oct 11, 2024 | nature.com | Florian Huber |Marion Arnaud |Fabrizio Benedetti |Jonathan Thevenet |Johanna Chiffelle |Markus K Muller | +7 more

AbstractThe accurate identification and prioritization of antigenic peptides is crucial for the development of personalized cancer immunotherapies. Publicly available pipelines to predict clinical neoantigens do not allow direct integration of mass spectrometry immunopeptidomics data, which can uncover antigenic peptides derived from various canonical and noncanonical sources.

Oct 11, 2024 | nature.com | Florian Huber |Marion Arnaud |Fabrizio Benedetti |Jonathan Thevenet |Johanna Chiffelle |Markus K Muller | +7 more

AbstractThe accurate identification and prioritization of antigenic peptides is crucial for the development of personalized cancer immunotherapies. Publicly available pipelines to predict clinical neoantigens do not allow direct integration of mass spectrometry immunopeptidomics data, which can uncover antigenic peptides derived from various canonical and noncanonical sources.

Jun 11, 2024 | rupress.org | Lausanne Branch |Johanna Chiffelle |Alexandre Harari

In cancer research, antigens have long been recognized as pivotal triggers of immune responses and potential therapeutic targets. Antigens are commonly categorized into tumor-associated antigens (TAAs) or canonical neoantigens (Peri et al., 2023). TAAs are self-antigens, showing varied expression patterns within tumors.

Apr 24, 2024 | nature.com | Matteo Morotti |Alizée J. Grimm |Helen Hope |Marion Arnaud |David Barras |Catherine Ronet | +14 more

AbstractExpansion of antigen-experienced CD8+ T cells is critical for the success of tumour-infiltrating lymphocyte (TIL)-adoptive cell therapy (ACT) in patients with cancer1. Interleukin-2 (IL-2) acts as a key regulator of CD8+ cytotoxic T lymphocyte functions by promoting expansion and cytotoxic capability2,3.